CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among […]